Skip to main content
. 2021 Apr 13;35(8):907–918. doi: 10.1007/s40263-021-00810-3
In a retrospective cohort of 185 patients with multiple sclerosis treated with ocrelizumab, 176 infections were reported, in 46.1% of patients.
Odds of infection in univariate and multivariable analyses were not uniform, with increasing IgA and IgG and multiple clinical factors being associated with reduced odds of infection.